Formulary Monographs [DIDANOSINE, 08180820]
|
|
DIDANOSINE
|
|
|
|
|
|
NRTI
|
|
|
A first-line component of a combination antiretroviral therapy regimenfor HIV-1 infected p atients.
|
|
|
Diarrhoea, neuropathy , chills or fever, rash, abdominal pain,weakness, headache and nausea/vomiting. Serious toxicities have included pancreatitis and lactic acidosis (which may be fatal), severe hepatomegaly with steatosis, retinal changes and optic neuritis and peripheral neuropathy . Concurrent use with hydroxy urea or stavudine may cause fatal pancreatitis, hepatotoxicity and neurotoxicity . Use with caution if imidazole antifungals, fluoroquinolone antimicrobials or ganciclovir are co-administered. Doses should be decreased with impaired renal function.
|
|
|
Adult: weighing greater than 60kg, 200mg twice daily . Weighing less than or equal to 60kg, 125mg twice daily . Pediatric 8 months and older: 120mg/square meter twice daily . 2 weeks - 8 months: 100mg/square meter twice daily . Take on an empty stomach.
|
|
|
Coadministration of Didanosine and allopurinol is contraindicated because systemic exposures of Didanosine are increased, which may increase Didanosine-associated toxicity
|
|
|
Reproduction studies have been performed in rats and rabbits at doses up to 12 and 14.2 times the estimated human exposure (based upon plasma levels), respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to Didanosine
|
|
|
The Centers for Disease Control and Prevention (CDC) and other experts recommend that HIV-infected women not breast-feed infants, regardless of antiretroviral therapy due to the risk of transmitting the virus through breastfeeding.
|
|
|
|